if we resume, a decade on the critical sunset, in terms of the enrichment level. at the same time, their efforts to weaponize, based on public information, paused, stops some years ago. we looked carefully to see if they resume. we would be focused on this like a hawk either way. to the point, and the chairman s point, the agreement does not address other malicious activities. we have two premises. one, when it comes to the activities, things would be it would encourage them to act with greater impunity. it does not take away from our ability to go at them in other
your stake in innate is more than the figure you reported to ethics officials when you became a nominee. and if you would listen to your committee staff, i think you would know that our belief is that there was a clerical error at the time the 278e happened. we don t know where it happened, whether it was on our end or the end of the individuals of oge. but there was not any malicious congressman, you also reported it in the questionnaire to the committee and you had to revise it yesterday because it was wrong. and the reason for that is because i when asked about the value, i thought it meant the value at the time that i purchased the stock, not the value at some nebulous time i want to get in another question. this weekend, the president issued an executive order instructing agencies to do everything possible to roll back the affordable care act.
then periodic transaction report on april 15. now, dr. price began hiss legislative effort related to the comprehensive joint replacement project in 2015. with one exception, all of dr. price s stocks are held in free broker-directed accounts. near he nor his wife, direct or provide input in investments in these accounts. innate immunno therapeutics is the one exception. dr. price decided to invest in, i ll just call it, based on public information regarding his work on multiple sclerosis treatments, as a disease. he has been intimately involved in treating for years. he directed the invesents based on hiswn research into the company, invested $10,000 in the company in january of 2015
let s listen in. not to put too fine a point on it, but we re right, and the next hhs secretary will play a pivotal role as we work to repeal obamacare and replace it with patient-centered reforms that will actually address costs, among other things. this will be an important endeavor, one that will and should get a lot of attention here today, but it should not be the soul focus of the next h shrks secretary. hhs has an annual budget of well over $1 trillion. let me repeat that. one department, $1 trillion. hhs encompasses the centers for medicare and medicaid services, the centers for disease, control, and prevention, the national institutes of health, the food and drug administration, and many others. it s no exaggeration to say that hhs touches more of the u.s. economy and affects the daily lives of more americans than any other part of the u.s.
in this committee, should continue to apply, regardless of who is president. if what we re seeing now is the new normal for every time control of the white house changes hands, the sfath, quite frankly, will be a much lesser institution. unfortunately, our committee has not been entirely immune to the hyperpoliticization of the nomination process. we saw that last week with the mnuchin hearing and i regret to say i think we ll see more of it today. i hope not. but i think during today s hearing, we re going to hear quite a bit during the process and claims that dr. price s nomination is being rushed and that the nominee hasn t, fully vetted. these allegations are simply untrue. president trump announced his attempt to nominate dr. price just three weeks after the election. dr. price submitted the required